Literature DB >> 22266361

Kuguacin J, a triterpeniod from Momordica charantia leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3.

Pornsiri Pitchakarn1, Shugo Suzuki, Kumiko Ogawa, Wilart Pompimon, Satoru Takahashi, Makoto Asamoto, Pornngarm Limtrakul, Tomoyuki Shirai.   

Abstract

In this study, we focused on the in vitro effects of Kuguacin J (KuJ), a purified component of bitter melon (Momordica charantia) leaf extract (BMLE), on the androgen-independent human prostate cancer cell line PC3 and the in vivo effect of dietary BMLE on prostate carcinogenesis using a PC3-xenograph model. KuJ exerted a strong growth-inhibitory effect on PC3 cells. Growth inhibition was mainly through G1-arrest: KuJ markedly decreased the levels of cyclins (D1 and E), cyclin-dependent kinases (Cdk2 and Cdk4) and proliferating cell nuclear antigen. Interestingly, KuJ also dramatically decreased the levels of survivin expressed by PC3 cells. In addition, KuJ exerted anti-invasive effects on PC3 cells, significantly inhibiting migration and invasion: KuJ inhibited secretion of the active forms of MMP-2, MMP-9 and uPA by PC3 cells. In addition, KuJ treatment significantly decreased the expression of membrane type 1-MMP (MT1-MMP) by PC3 cells. In vivo, 1% and 5% BMLE in the diet resulted in 63% and 57% inhibition of PC3 xenograft growth without adverse effect on host body weight. Our results suggest that KuJ is a promising new candidate chemopreventive and chemotherapeutic agent for prostate cancer. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266361     DOI: 10.1016/j.fct.2012.01.009

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  8 in total

1.  In vitro and in vivo study of inhibitory potentials of α-glucosidase and acetylcholinesterase and biochemical profiling of M. charantia in alloxan-induced diabetic rat models.

Authors:  Fatma Hussain; Javaria Hafeez; Amany S Khalifa; Muhammad Naeem; Tayyab Ali; Emad M Eed
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  In vivo hypoglycemic effect of methanolic fruit extract of Momordica charantia L.

Authors:  W Nkambo; N G Anyama; B Onegi
Journal:  Afr Health Sci       Date:  2013-12       Impact factor: 0.927

3.  Antibacterial and Antiproliferative Activities of Plumericin, an Iridoid Isolated from Momordica charantia Vine.

Authors:  Jutamas Saengsai; Sumonthip Kongtunjanphuk; Nuttawan Yoswatthana; Tanawan Kummalue; Weena Jiratchariyakul
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-07       Impact factor: 2.629

4.  Comparative Study of Hydroalcoholic Extracts of Momordica charantia L. against Foodborne Pathogens.

Authors:  Kalpna Rakholiya; P Vaghela; T Rathod; Sumitra Chanda
Journal:  Indian J Pharm Sci       Date:  2014-03       Impact factor: 0.975

5.  Effects of sophorae radix on human gastric and colorectal adenocarcinoma cells: sophorae radix and cancer cells.

Authors:  Min-Chul Kim; Bora Lim; Hee-Jung Lee; Hyung-Woo Kim; Young-Kyu Kwon; Byung-Joo Kim
Journal:  J Pharmacopuncture       Date:  2012-06

Review 6.  Recent Advances in Momordica charantia: Functional Components and Biological Activities.

Authors:  Shuo Jia; Mingyue Shen; Fan Zhang; Jianhua Xie
Journal:  Int J Mol Sci       Date:  2017-11-28       Impact factor: 5.923

7.  Cyclohexanone curcumin analogs inhibit the progression of castration-resistant prostate cancer in vitro and in vivo.

Authors:  Sariya Mapoung; Shugo Suzuki; Satoshi Fuji; Aya Naiki-Ito; Hiroyuki Kato; Supachai Yodkeeree; Chitchamai Ovatlarnporn; Satoru Takahashi; Pornngarm Limtrakul Dejkriengkraikul
Journal:  Cancer Sci       Date:  2018-12-21       Impact factor: 6.716

Review 8.  Bitter Melon (Momordica Charantia), a Nutraceutical Approach for Cancer Prevention and Therapy.

Authors:  Subhayan Sur; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.